PMID- 34763955
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220531
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 83
IP  - 1
DP  - 2022 Jan
TI  - Association of HLA-G 3'UTR polymorphisms and haplotypes with colorectal cancer 
      susceptibility and prognosis.
PG  - 39-46
LID - S0198-8859(21)00248-2 [pii]
LID - 10.1016/j.humimm.2021.10.003 [doi]
AB  - Human leukocyte antigen (HLA)-G has been considered as an immune modulator in 
      several types of cancers. Its genetic polymorphisms may potentially affect the 
      risk of developing colorectal cancer (CRC). The overall purpose of this study was 
      to analyze the implication of HLA-G 3'untranslated region (3'UTR) polymorphisms 
      particularly 14 pb insertion/deletion (Ins/Del; rs371194629) and + 3142C/G 
      (rs1063320) in CRC susceptibility and progression. A comparative analysis between 
      patients (N = 233) and controls (N = 241) demonstrated that Del allele (Odds 
      Ratios (OR) = 1.41, 95% CI = 1.091-1.819, p = 0.008), the homozygous Del/Del 
      genotype (OR = 1.80, 95% CI = 1.205-2.664, p = 0.003) and the codominant C/G 
      genotype (OR = 1.59, 95% CI = 1.106-2.272, p = 0.013) were associated to CRC 
      risk. As expected, the DelG haplotype was associated with CRC susceptibility 
      (OR = 1.47, 95% CI = 1.068-2.012, p = 0.018). Assessment of patients' survival by 
      Kaplan-Meier analysis indicated that the Del allele and the homozygous Del/Del 
      genotype were associated with reduced event free survival (EFS) (Respectively, 
      p = 0.009 and p = 0.05). Interestingly, the Del allele and the homozygous Del/Del 
      genotype have been revealed as independent prognostic factors for poor EFS in 
      patients with CRC. Additionally, haplotypes analysis revealed that DelG haplotype 
      was linked with significant increase in CRC risk (log-rank; EFS: p = 0.02). 
      Inversely, the InsC haplotype was associated with a significant reduced CRC risk 
      (log-rank; Overall survival (OS): p < 10(-6); EFS: p = 0.01). Multivariate Cox 
      regression analysis revealed that the InsC haplotype was independently associated 
      with significantly longer EFS (p = 0.021, HR = 0.636, 95% CI = 0.433-0.935). 
      These findings support the implication of HLA-G polymorphisms in the CRC 
      susceptibility suggesting HLA-G as a potent prognostic and predictive indicator 
      for CRC. Insight into mechanisms underlying HLA-G polymorphisms could allow for 
      the development of targeted care for CRC patients according to their genetic 
      profile.
CI  - Copyright (c) 2021 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Dhouioui, Sabrine
AU  - Dhouioui S
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia.
FAU - Laaribi, Ahmed-Baligh
AU  - Laaribi AB
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia.
FAU - Boujelbene, Nadia
AU  - Boujelbene N
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia; Department of Pathology, Salah Azaiz 
      Institute, Faculty of Medicine, Tunis, Tunisia.
FAU - Jelassi, Refka
AU  - Jelassi R
AD  - LR11-IPT-06: Laboratory of Medical Parasitology, Biotechnology and Biomolecules, 
      Pasteur Institute of Tunis, Tunis, Tunisia.
FAU - Ben Salah, Hamza
AU  - Ben Salah H
AD  - LR11-IPT-06: Laboratory of Medical Parasitology, Biotechnology and Biomolecules, 
      Pasteur Institute of Tunis, Tunis, Tunisia.
FAU - Bellali, Hedia
AU  - Bellali H
AD  - Epidemiology and Public Health Department, Medical Faculty of Tunis. Head of 
      Clinical Epidemiology Department, Habib Thameur Hospital, Tunis, Tunisia.
FAU - Ouzari, Hadda-Imene
AU  - Ouzari HI
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia.
FAU - Mezlini, Amel
AU  - Mezlini A
AD  - Department of Medical Oncology, Salah Azaiz Institute, Faculty of Medicine, 
      Tunis, Tunisia.
FAU - Zemni, Ines
AU  - Zemni I
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia; Department of Surgical Oncology, Salah 
      Azaiz Institute, Faculty of medicine, Tunis, Tunisia.
FAU - Chelbi, Hanene
AU  - Chelbi H
AD  - LR11-IPT-06: Laboratory of Medical Parasitology, Biotechnology and Biomolecules, 
      Pasteur Institute of Tunis, Tunis, Tunisia.
FAU - Zidi, Ines
AU  - Zidi I
AD  - Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, 
      University Tunis El Manar, Tunis, Tunisia. Electronic address: 
      ines.zidi@istmt.utm.tn.
LA  - eng
PT  - Journal Article
DEP - 20211109
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (3' Untranslated Regions)
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Case-Control Studies
MH  - *Colorectal Neoplasms/genetics
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - *HLA-G Antigens/genetics
MH  - Haplotypes
MH  - Humans
MH  - Polymorphism, Genetic
MH  - Prognosis
OTO - NOTNLM
OT  - +3142C/G
OT  - 14 pb insertion/deletion
OT  - Colorectal cancer
OT  - HLA-G
OT  - Polymorphism
OT  - SNP
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/11/13 06:00
MHDA- 2022/03/17 06:00
CRDT- 2021/11/12 05:44
PHST- 2021/05/21 00:00 [received]
PHST- 2021/09/23 00:00 [revised]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2021/11/12 05:44 [entrez]
AID - S0198-8859(21)00248-2 [pii]
AID - 10.1016/j.humimm.2021.10.003 [doi]
PST - ppublish
SO  - Hum Immunol. 2022 Jan;83(1):39-46. doi: 10.1016/j.humimm.2021.10.003. Epub 2021 
      Nov 9.